Oncology Central

Study suggests anti-PD-1 therapy could be enhanced with SBRT

According to a recent Phase I study, outcomes of patients with advanced solid tumors and multiple metastatic sites may be improved by treatment with multisite stereotactic body radiotherapy (SBRT) prior to treatment with the anti-PD-1 immunotherapeutic drug, pembrolizumab. The study demonstrated the combination was generally well-tolerated and resulted in abscopal responses.
To view restricted content, please:



News Headlines

Leave A Comment

Please wait...

Would you like access to more immuno-oncology content?

Register with Oncology Central to find out the latest news, opinions and journal articles published in the oncology field by leading experts.